Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Apricus holds US rights for Vitaros as sells the rest to Ferring

Thursday, March 9, 2017 7:49
% of readers think this story is Fact. Add your two cents.

Apricus Biosciences Inc. (NASDAQ:APRI) shares opened 18.5% higher on Thursday at $3.29 after confirming overnight it had completed the sale to Ferring International Center SA, a privately listed firm, of Apricus’ ex-US assets and rights related to Vitaros.

Vitaros is Apricus’ on-demand topical cream indicated for the treatment of patients with erectile dysfunction.

Ferring is Apricus’ commercial partner for Vitaros in Latin America and certain parts of Europe and Asia.

Apricus will retain its Vitaros rights in the US and it remains on track to re-submit the Vitaros New Drug Application to the Food and Drug Administration in the third quarter of 2017.

However, the opening share price was diluted from pre-market activity which saw the stock up as much as 26%.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.